Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9
- 1 January 2004
- journal article
- research article
- Published by Informa UK Limited in Xenobiotica
- Vol. 34 (1), 49-60
- https://doi.org/10.1080/00498250310001636868
Abstract
Methods for the co-expression in Escherichia coli of human cytochrome P450 (CYP) 2C8 and CYP2C9 with NADPH-cytochrome P450 reductase (OxR) to produce a catalytically active system were compared. Approaches assessed were expression of a CYP:OxR fusion construct, bicistronic plasmids, simultaneous transformation with CYP and OxR plasmids, and separate expression of CYP and OxR with reconstitution of activity by mixing the bacterial membranes. Two N-terminal modifications (A3-20 and 17a-leader) of the individual P450s were additionally investigated. Each approach gave efficient expression of CYP2C8 and CYP2C9, but the bicistronic constructs under the expression conditions used gave low OxR expression and low catalytic activity. CYP expression was higher with the A3-20 construct for CYP2C9 and with the 17a-presequence construct for CYP2C8. Using torsemide as substrate, all methods gave catalytically active systems with Km values similar to human liver microsomes. Mixing bacterial membranes containing separately expressed CYP and OxR reconstituted a catalytically active system with the A3-20 construct for CYP2C9 but not for CYP2C8, and with neither of the 17a- presequence constructs. OxR co-expressed with CYP in the same membrane interacted with CYP to reconstitute activity more effectively than addition of exogenous OxR membranes. Expression construct and OxR co-expression strategy should be individualized for CYP isoforms.Keywords
This publication has 22 references indexed in Scilit:
- Genetically Engineered Bacterial Cells Co-expressing Human Cytochrome P450 with NADPH-cytochrome P450 Reductase: Prediction of Metabolism and Toxicity of Drugs in HumansDrug Metabolism and Pharmacokinetics, 2002
- Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acidPharmacogenetics, 2001
- Common and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical ToxicityChemical Research in Toxicology, 2001
- Cytochrome P450 2C is an EDHF synthase in coronary arteriesNature, 1999
- High Catalytic Activity of Human Cytochrome P450 Co-expressed with Human NADPH-Cytochrome P450 Reductase in Escherichia coliBiochemical Pharmacology, 1998
- Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coliFEBS Letters, 1996
- Construction of a Human Cytochrome P450 1A1:Rat NADPH–Cytochrome P450 Reductase Fusion Protein cDNA and Expression inEscherichia coli,Purification, and Catalytic Properties of the Enzyme in Bacterial Cells and after PurificationArchives of Biochemistry and Biophysics, 1996
- Coexpression of Mammalian Cytochrome P450 and Reductase inEscherichia coliArchives of Biochemistry and Biophysics, 1996
- [2] Construction of plasmids and expression in Escherichia coli of enzymatically active fusion proteins containing the heme-domain of a P450 linked to NADPH-P450 reductaseMethods in enzymology, 1996
- Expression of Modified Human Cytochrome P450 3A4 in Escherichia coli and Purification and Reconstitution of the EnzymeArchives of Biochemistry and Biophysics, 1993